FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * OXFORD BIOSCIENCE PARTNERS IV LP   2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 222 BERKELEY ST. 3. Date of Earliest Transaction (Month/Day/Year) 07/29/2005 (Street) BOSTON, MA 02116 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Common Stock Warrant (right to buy)

$ 8.148

07/29/2005

P

89,900

10/17/2005

04/19/2010

Common Stock

89,900

$ 3.09

236,500

D (1)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
OXFORD BIOSCIENCE PARTNERS IV LP 222 BERKELEY ST. BOSTON, MA 02116		X
MRNA FUND II LP 222 BERKELEY ST. BOSTON, MA 02116		X
OBP MANAGEMENT IV LP 222 BERKELEY ST. BOSTON, MA 02116		X
BARNES JEFFREY T 222 BERKELEY ST. BOSTON, MA 02116		X
CARTHY MARK 222 BERKELEY ST. BOSTON, MA 02116		X
FLEMING JONATHAN 222 BERKELEY ST. BOSTON, MA 02116		X
LYTTON MICHAEL 222 BERKELEY ST. BOSTON, MA 02116		X
WALTON ALAN G 222 BERKELEY ST. BOSTON, MA 02116	X	X

Signatures

/s/ Raymond Charest, as attorney-in-fact for Jonathan J. Fleming, as general partner of the general partner of Oxford Bioscience Partners IV L.P.		08/02/2005
**Signature of Reporting Person		Date
/s/ Alexia Pearsall, as attorney-in-fact for Jonathan J. Fleming, as general partner of the general partner of mRNA Fund II L.P.		08/02/2005
**Signature of Reporting Person		Date
/s/ Raymond Charest, as attorney-in-fact for Jonathan J. Fleming, as general partner of OBP Management IV L.P.		08/02/2005
**Signature of Reporting Person		Date
/s/ Raymond Charest, as attorney-in-fact for Jeffrey T. Barnes		08/02/2005
**Signature of Reporting Person		Date
/s/ Raymond Charest, as attorney-in-fact for Mark P. Carthy		08/02/2005
**Signature of Reporting Person		Date
/s/ Raymond Charest, as attorney-in-fact for Jonathan J. Fleming		08/02/2005
**Signature of Reporting Person		Date
/s/ Michael E. Lytton		08/02/2005
**Signature of Reporting Person		Date
/s/ Raymond Charest, as attorney-in-fact for Alan G. Walton		08/02/2005
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Securities held of record by Oxford Bioscience Partners IV L.P. ("Oxford IV"). By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA Fund II L.P. ("mRNA") may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. OBP Management IV L.P. ("OBP IV") (as the general partner of Oxford IV), may also be deemed to own beneficially the shares held of record by Oxford IV. Each of Messrs. Barnes, Carthy, Fleming, Lytton, and Walton (who is a Director of the Issuer), the individual general partners of OBP IV, may be deemed to own beneficially the shares held by Oxford IV. The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.